Document Actions

You are here: Home Faculty Professors Eder


Prof. Dr.
Matthias Eder

Department of Nuclear Medicine
German Cancer Consortium (DKTK)
Phone: 0049-761-270-39910


  • 2006-2009 Doctoral thesis, University of Heidelberg and German Cancer Research Center Heidelberg
  • 2009-2012 German Cancer Research Center, Heidelberg, postdoc
  • 2013-2015 Group leader “Radiopharmaceutical Sciences” in the Division Radiopharmaceutical Chemistry, German Cancer Research Center Heidelberg
  • 2015-2017 Research Group in the Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center Heidelberg and University Hospital, Heidelberg
  • Since 2017 Full Professor (W3) of Radiopharmaceutical Development, Medical Center – University of Freiburg/ DKTK

Focus of research

  • Translational radiopharmaceutical sciences
  • Development of novel radiopharmaceuticals for the diagnosis and therapy in Nuclear Medicine 
  • Theranostics

Selected publications

  • Kratochwil C, ... Eder M, Kopka K, Haberkorn U. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016; 57:1170-6.
  • Benesova M, ... Eder M. Linker Modification Strategies to Control the Prostate-Specifc Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTAConjugated PSMA Inhibitors. Journal of Medicinal Chemistry. 2016; 59:1761-75.
  • Benesova M, ... Eder M. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Journal of Nuclear Medicine 2015; 56:914-20.
  • Afshar-Oromieh A, ... Eder M, ... Haberkorn U. The diagnostic value of PET/CT imaging with the Galabelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42:197-209.
  • Eder et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23(4):688-97.

Research methods

  • Biotechnological methods for the development of novel radiopharmaceuticals in nuclear medicine